<DOC>
	<DOCNO>NCT01759251</DOCNO>
	<brief_summary>The purpose international post-marketing observational program investigate effectiveness betahistine dihydrochloride ( Betaserc® ) tablets assess course vestibular vertigo treatment discontinuation population Russia Ukraine outpatient suffer vestibular vertigo pragmatic clinical setting . Exploratory analysis result participate country may expect provide insight subjective circumstance vestibular vertigo patient wider usual range gender , underlie ICD-10 diagnosis , national cultural situation .</brief_summary>
	<brief_title>Effectiveness Betaserc® ( Betahistine Dihydrochloride ) Patients With Vestibular Vertigo Routine Practice</brief_title>
	<detailed_description>A prospective , multicentre , non-interventional , non-randomized , non-controlled , single arm , post-marketing observational program patient betahistine dihydrochloride ( Betaserc® ) tablets prescribed usual manner maximal recommend daily dose 48 mg accordance locally approve label . Over program period physician free adjust betahistine dihydrochloride dose accord country approve label . Adult outpatient vestibular vertigo treat betahistine dihydrochloride per locally approve label enrol program . The program consist observational treatment period ( 2 month ) follow-up period ( 2 month , evaluation course vestibular vertigo treatment completion ) .</detailed_description>
	<mesh_term>Vertigo</mesh_term>
	<mesh_term>Dizziness</mesh_term>
	<mesh_term>Betahistine</mesh_term>
	<criteria>Inclusion Criteria Male female 18 year old . Patients vestibular vertigo know unknown origin , physician decide prescribe 48 mg betahistine dihydrochloride ( Betaserc® ) accordance locally approve label . Patients willing able provide authorization investigator use and/or disclose personal and/or health data . Patients start betahistine dihydrochloride ( Betaserc® ) therapy 5 day priory sign Patient Authorization ( Consent ) Use/Disclosure Data . Exclusion Criteria Patients condition , opinion Investigator , make patient unsuitable inclusion base clinical judgment . Labeled contraindication betahistine dihydrochloride ( Betaserc® ) treatment . Patients middle inner ear infection . Patient psychiatric disorder , significant neurological disorder spinal cord damage . Patients receive agent peripheral vestibular vertigo diuretic , transtympanic gentamycin , cinnarizine , competitive antagonist histamine , block H1 histamine receptor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Meniere Disease</keyword>
	<keyword>Betahistine Dihydrochloride</keyword>
	<keyword>Vertigo</keyword>
</DOC>